- Home
- GGZ vs MGNX Comparison
GGZ vs MGNX Comparison
Compare GGZ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGZ
- MGNX
- Stock Information
- Founded
- GGZ 2013
- MGNX 2000
- Country
- GGZ United States
- MGNX United States
- Employees
- GGZ N/A
- MGNX N/A
- Industry
- GGZ Investment Managers
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- GGZ Finance
- MGNX Health Care
- Exchange
- GGZ Nasdaq
- MGNX Nasdaq
- Market Cap
- GGZ 114.8M
- MGNX 99.7M
- IPO Year
- GGZ N/A
- MGNX 2013
- Fundamental
- Price
- GGZ $14.38
- MGNX $1.78
- Analyst Decision
- GGZ
- MGNX Hold
- Analyst Count
- GGZ 0
- MGNX 6
- Target Price
- GGZ N/A
- MGNX $3.20
- AVG Volume (30 Days)
- GGZ 12.8K
- MGNX 630.9K
- Earning Date
- GGZ 01-01-0001
- MGNX 11-04-2025
- Dividend Yield
- GGZ 5.39%
- MGNX N/A
- EPS Growth
- GGZ N/A
- MGNX N/A
- EPS
- GGZ 1.75
- MGNX N/A
- Revenue
- GGZ N/A
- MGNX $165,495,000.00
- Revenue This Year
- GGZ N/A
- MGNX N/A
- Revenue Next Year
- GGZ N/A
- MGNX N/A
- P/E Ratio
- GGZ $6.79
- MGNX N/A
- Revenue Growth
- GGZ N/A
- MGNX 303.47
- 52 Week Low
- GGZ $9.43
- MGNX $0.99
- 52 Week High
- GGZ $12.50
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- GGZ 50.23
- MGNX 51.87
- Support Level
- GGZ $14.35
- MGNX $1.69
- Resistance Level
- GGZ $14.77
- MGNX $1.83
- Average True Range (ATR)
- GGZ 0.18
- MGNX 0.10
- MACD
- GGZ -0.04
- MGNX 0.00
- Stochastic Oscillator
- GGZ 13.40
- MGNX 56.00
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.